Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. It is a complicated disease state involving an irregular heart rate and rhythm. AF generally affects the aging population and is classified as either valvular AF (VAF) or nonvalvular AF (NVAF). The two differ based on the patient’s valve status and treatment strategies. AF treatment is directed toward rate control, with or without rhythm control, and anticoagulation for prevention of cardioembolic stroke. Several direct oral anticoagulants (edoxaban, apixaban, rivaroxaban, dabigatran) have recently gained approval for use in NVAF. Pharmacists should educate patients about potential drug-drug interactions and adverse effects with this class of medications.
| Original language | English (US) |
|---|---|
| Pages | 32-35 |
| Number of pages | 4 |
| Volume | 42 |
| No | 2 |
| Specialist publication | U.S. Pharmacist |
| State | Published - Feb 2017 |
All Science Journal Classification (ASJC) codes
- Pharmacy
- Pharmacology
- Pharmaceutical Science
Fingerprint Dive into the research topics of 'Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation'. Together they form a unique fingerprint.
Cite this
Hoie, E. B., O’Brien, K. K., Neighbors, K., Castillo, S. L., & Begley, K. J. (2017). Direct oral anticoagulants for the prevention of stroke in nonvalvular atrial fibrillation. U.S. Pharmacist, 42(2), 32-35.